Urovant sciences presents positive clinical efficacy & safety data on lead drug candidate vibegron at virtual american urological association annual meeting

Urovant sciences (nasdaq: urov) announced today that data from the vibegron empowur 52-week extension study (nct03583372) and data by age groups from

AXNX Ratings Summary

AXNX Quant Ranking